Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional) | RFA DK 25 017

Opportunity Information: Apply for RFA DK 25 017

This funding opportunity (RFA-DK-25-017) is an NIH cooperative agreement (U01; clinical trial optional) intended to continue and strengthen a multi-site clinical research consortium focused on diabetes that develops during or after acute pancreatitis, with special emphasis on Type 1 diabetes (T1D). The overall structure is a single coordinated consortium made up of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CCs). Applicants responding to this specific NOFO are applying to serve as a Clinical Center; the DCC is competed separately under RFA-DK-25-018. Because it is a U01 cooperative agreement, awardees should expect substantial NIH programmatic involvement and close coordination across sites to deliver a unified study rather than a collection of unrelated projects.

Scientifically, the consortium is being built to run a prospective, longitudinal, observational study tracking people who experience acute pancreatitis and then develop impaired glucose tolerance or diabetes either during the pancreatitis episode or later. The core goal is to understand how often diabetes occurs in this context, how it evolves clinically over time, and what forms it takes, including whether some cases represent true T1D as opposed to other diabetes subtypes that can follow pancreatic injury. A major emphasis is on clarifying etiology and pathophysiology: in practical terms, this means carefully defining and phenotyping diabetes after acute pancreatitis, documenting the clinical course, and collecting the kinds of data and biospecimens needed to distinguish immune-mediated T1D from other mechanisms that can lead to hyperglycemia after pancreatic inflammation.

A second major thrust is prediction and stratification. The consortium is expected to identify immune and genetic risk factors, along with measurable biomarkers, that can help predict who among acute pancreatitis survivors is most likely to develop T1D (and other diabetes forms) afterward. The NOFO specifically calls for work in a racially, ethnically, and geographically diverse study population and across acute pancreatitis cases with different identifiable causes, which signals that recruitment plans, retention strategies, and site capabilities to reach diverse communities will be important. In general, Clinical Centers would be responsible for participant identification and enrollment, standardized clinical characterization and follow-up, biospecimen collection and handling under common protocols, and consistent data capture that feeds into the consortium-wide dataset managed in partnership with the DCC.

From an administrative standpoint, the opportunity falls under CFDA 93.847, is categorized under food and nutrition/health, and is offered by the National Institutes of Health. The listed award ceiling for this announcement is $350,000. The original application due date shown is 2024-11-19. While the posting does not specify the exact number of anticipated awards in the excerpt provided, the consortium design indicates up to 10 Clinical Centers plus one separately funded DCC.

Eligibility is broad and includes many domestic organization types: state, county, and local governments; public and state-controlled and private institutions of higher education; federally recognized tribal governments and other tribal organizations; nonprofits (including 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses) and small businesses; independent school districts; special districts; and public housing/Indian housing authorities. The announcement also highlights categories such as HBCUs, Hispanic-serving institutions, AANAPISIs, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based/community-based organizations, U.S. territories or possessions, and certain regional organizations. At the same time, non-U.S. entities and non-U.S. components of U.S. organizations are not eligible to apply as applicants, though foreign components (as NIH defines them) are allowed, meaning a U.S.-based applicant could potentially include certain international elements if justified and compliant with NIH policy.

In plain terms, this NOFO is looking for clinical sites that can work as part of a tightly coordinated network to follow acute pancreatitis patients over time, detect and classify post-pancreatitis dysglycemia and diabetes with an emphasis on identifying immune-mediated T1D, and contribute high-quality standardized clinical data and specimens. The long-term value of the program is to clarify what post-acute-pancreatitis diabetes really looks like across populations, why it happens in some people and not others, and which immune, genetic, or biomarker signals could support earlier identification, better classification, and ultimately more targeted prevention or intervention strategies.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2024-08-16.
• Applicants must submit their applications by 2024-11-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $350,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 25 017

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: